Aldesleukin
- Atc Codes:L03AC01
- CAS Codes:110942-02-4
- PHARMGKB ID:110942-02-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Proleukin; Belgium: Proleukin; Czech Republic: Proleukin; Denmark: Proleukin; Finland: Proleukin; France: Proleukin; Germany: Proleukin; Greece: Proleukin; Hungary: Proleukin; Ireland: Proleukin; Italy: Proleukin; Lithuania: Proleukin; Luxembourg: Proleukin; Malta: Proleukin; Netherlands: Proleukin; Poland: Proleukin; Portugal: Proleukin; Slovakia: Proleukin; Spain: Proleukin; UK: Proleukin.
North America
Canada: Proleukin; USA: Proleukin.
Latin America
Argentina: Proleukin; Brazil: Proleukin; Mexico: Proleukin.
Drug combinations
Aldesleukin, Cisplatin, Dacarbazine, and Interferon Alpha-2b
Chemistry
Aldesleukin: C~690~H~1115~N~177~O~203~S~6~. Mw: 15600.01. (1) 2-133-Interleukin 2 (human reduced), 125-L-serine-; (2) 125-L-Serine-2-133-interleukin 2 (human reduced). CAS-110942-02-4 (1990).
Pharmacologic Category
Antineoplastic Agents; Immunostimulants. Biological Response Response Modifiers. (ATC-Code: L03AC01).
Mechanism of action
Promotes proliferation, differentiation, and recruitment of T and B cells, natural killer cells, and thymocytes. Cytolytic activity in a subset of lymphocytes and subsequent interactions between the immune system and malignant cells. Stimulates lymphokine-activated killer cells and tumor-infiltrating lymphocytes.
Therapeutic use
Treatment of metastatic renal cell cancer and metastatic melanoma.
Pregnancy and lactiation implications
Use during pregnancy only if benefits to the mother outweigh potential risk to the fetus. Contraception is recommended for fertile males or females using this medication. Not recommended during lactation.
Unlabeled use
HIV infection, AIDS, Non-Hodgkin lymphoma.
Contraindications
Hypersensitivity to aldesleukin or any component of the formulation. Abnormal thallium stress or pulmonary function tests. Patients who have had an organ allograft. Retreatment in sustained ventricular tachycardia, refractory cardiac rhythm disturbances, angina or myocardial infarction, intubation, pericardial tamponade, renal dialysis, coma, toxic psychosis, repetitive or refractory seizures, bowel ischemia/perforation, gastrointestinal bleeding requiring surgery.
Warnings and precautions
Hazardous agent. Capillary leak syndrome (risk of hypotension and reduced organ perfusion with high-dose therapy). Mental status changes (irritability, confusion, depression) can occur and may indicate bacteremia, hypoperfusion, CNS malignancy, or CNS toxicity. Impaired neutrophil function (risk for sepsis, bacterial endocarditis, and central line-related Gram-positive infections). Continued treatment in lethargy or somnolence may result in coma. Caution in autoimmune/inflammatory disorders (may exacerbate condition). Evaluation and treatment for CNS metastases and negative scan prior to treatment.